OSE is advancing an "Immunotherapy 2.0" future by leveraging MAbSilico’s artificial intelligence-powered software solutions and professional services to accelerate and further optimize the development ...
NANTES, France, June 11, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that the United States Patent and Trademark Office (USPTO) has issued the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results